Mesoblast Limited (MEOBF) files Form 6-K on director interest change

Rhea-AI Filing Summary

Mesoblast Limited submitted a foreign issuer report to the U.S. SEC for December 2025. The company notes that on December 23, 2025 it lodged with the Australian Securities Exchange a new issue announcement and a change of director’s interest notice (Appendix 3Y), which is attached as an exhibit to this report and incorporated by reference. The filing is administrative in nature and centers on disclosure of director shareholding changes and related new issue details rather than operating or financial results.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of December 2025

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On December 23, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: December 24, 2025

INDEX TO EXHIBITS

Item
99.1						Appendix 3Y of Mesoblast Ltd, dated December 23, 2025.

FAQ

What does Mesoblast Limited (MEOBF) report in this December 2025 Form 6-K?

The company reports that it filed with the Australian Securities Exchange a new issue announcement and a change of director’s interest notice (Appendix 3Y) on December 23, 2025, and attaches that document as an exhibit.

What is the attached Exhibit 99.1 in Mesoblast Limited's (MEOBF) Form 6-K?

Exhibit 99.1 is the Appendix 3Y of Mesoblast Ltd, dated December 23, 2025, which is a change of director’s interest notice associated with a new issue announcement.

Does this Mesoblast (MEOBF) Form 6-K include financial results or earnings data?

No. The report describes a new issue announcement and change of director’s interest notice and does not contain earnings or detailed financial tables in the provided content.

Who signed the December 2025 Mesoblast Limited (MEOBF) Form 6-K?

The report was signed on behalf of Mesoblast Limited by Niva Sivakumar, who is identified as the Company Secretary.

What is the main purpose of Mesoblast Limited’s (MEOBF) December 2025 Form 6-K?

The main purpose is to furnish U.S. investors with the same information released in Australia, specifically the new issue announcement and director interest changes disclosed in Appendix 3Y.

Where is Mesoblast Limited (MEOBF) incorporated and where are its principal executive offices located?

Mesoblast Limited is incorporated in Australia and its principal executive offices are located at Level 38, 55 Collins Street, Melbourne 3000, Australia.